过氧化物酶体增殖物激活受体在非酒精性脂肪性肝病发病机制及治疗中的作用
Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease.
作者信息
Kallwitz Eric R, McLachlan Alan, Cotler Scott J
机构信息
Department of Medicine, University of Illinois, 840 S Wood Street, 7th Floor, MC 716, Chicago, IL 60612, USA.
出版信息
World J Gastroenterol. 2008 Jan 7;14(1):22-8. doi: 10.3748/wjg.14.22.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is highly prevalent and can result in nonalcoholic steatohepatitis (NASH) and progressive liver disease including cirrhosis and hepatocellular carcinoma. A growing body of literature implicates the peroxisome proliferators-activated receptors (PPARs) in the pathogenesis and treatment of NAFLD. These nuclear hormone receptors impact on hepatic triglyceride accumulation and insulin resistance. The aim of this review is to describe the data linking PPAR alpha and PPAR gamma to NAFLD/NASH and to discuss the use of PPAR ligands for the treatment of NASH.
摘要
非酒精性脂肪性肝病（NAFLD）非常普遍，可导致非酒精性脂肪性肝炎（NASH）以及包括肝硬化和肝细胞癌在内的进行性肝病。越来越多的文献表明，过氧化物酶体增殖物激活受体（PPARs）参与了NAFLD的发病机制和治疗。这些核激素受体影响肝脏甘油三酯的积累和胰岛素抵抗。本综述的目的是描述将PPARα和PPARγ与NAFLD/NASH联系起来的数据，并讨论使用PPAR配体治疗NASH的情况。
相似文献
1
Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease.过氧化物酶体增殖物激活受体在非酒精性脂肪性肝病发病机制及治疗中的作用
World J Gastroenterol. 2008 Jan 7;14(1):22-8. doi: 10.3748/wjg.14.22.
2
[PPAR and NASH].[过氧化物酶体增殖物激活受体与非酒精性脂肪性肝炎]
Nihon Rinsho. 2006 Jun;64(6):1089-94.
3
RLA8-A New and Highly Effective Quadruple PPAR-// and GPR40 Agonist to Reverse Nonalcoholic Steatohepatitis and Fibrosis.RLA8-一种新型高效四重 PPAR-//和 GPR40 激动剂，可逆转非酒精性脂肪性肝炎和肝纤维化。
J Pharmacol Exp Ther. 2019 Apr;369(1):67-77. doi: 10.1124/jpet.118.255216. Epub 2019 Feb 11.
4
Nonalcoholic fatty liver disease: from steatosis to cirrhosis.非酒精性脂肪性肝病：从脂肪变性到肝硬化
Hepatology. 2006 Feb;43(2 Suppl 1):S99-S112. doi: 10.1002/hep.20973.
5
Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease.过氧化物酶体增殖物激活受体及其激动剂在非酒精性脂肪性肝病中的作用
J Clin Exp Hepatol. 2019 Nov-Dec;9(6):731-739. doi: 10.1016/j.jceh.2019.06.004. Epub 2019 Jul 2.
6
Peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms in nonalcoholic fatty liver disease: a study in Brazilian patients.过氧化物酶体增殖物激活受体α和γ2 多态性与非酒精性脂肪性肝病：巴西患者的研究。
Gene. 2013 Oct 25;529(2):326-31. doi: 10.1016/j.gene.2013.06.091. Epub 2013 Jul 24.
7
From the metabolic syndrome to NAFLD or vice versa?从代谢综合征到非酒精性脂肪性肝病，或者反之亦然？
Dig Liver Dis. 2010 May;42(5):320-30. doi: 10.1016/j.dld.2010.01.016. Epub 2010 Mar 6.
8
The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice.过氧化物酶体增殖物激活受体 α 的转录抑制活性对于预防小鼠肝纤维化是必需且充分的。
Hepatology. 2014 Nov;60(5):1593-606. doi: 10.1002/hep.27297. Epub 2014 Oct 1.
9
Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment.细胞因子在脂肪肝发病机制及疾病进展为脂肪性肝炎中的作用：对治疗的启示
Am J Gastroenterol. 2008 Apr;103(4):1036-42. doi: 10.1111/j.1572-0241.2007.01709.x. Epub 2008 Jan 2.
10
New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.新型过氧化物酶体增殖物激活受体激动剂：治疗动脉粥样硬化性血脂异常和非酒精性脂肪性肝病的潜在药物。
Expert Opin Pharmacother. 2014 Mar;15(4):493-503. doi: 10.1517/14656566.2014.876992. Epub 2014 Jan 16.
引用本文的文献
1
Fat-1 Ameliorates Metabolic Dysfunction-Associated Fatty Liver Disease and Atherosclerosis through Promoting the Nuclear Localization of PPARα in Hamsters.Fat-1通过促进仓鼠体内PPARα的核定位改善代谢功能障碍相关的脂肪性肝病和动脉粥样硬化。
Research (Wash D C). 2025 Mar 6;8:0577. doi: 10.34133/research.0577. eCollection 2025.
2
Wnt/β-catenin signaling activation promotes lipogenesis in the steatotic liver via physical mTOR interaction.Wnt/β-catenin 信号通路的激活通过物理上的 mTOR 相互作用促进脂肪变性肝脏的脂肪生成。
Front Endocrinol (Lausanne). 2023 Dec 13;14:1289004. doi: 10.3389/fendo.2023.1289004. eCollection 2023.
3
Hyodeoxycholic acid ameliorates nonalcoholic fatty liver disease by inhibiting RAN-mediated PPARα nucleus-cytoplasm shuttling.熊去氧胆酸通过抑制 RAN 介导的 PPARα 核质穿梭改善非酒精性脂肪性肝病。
Nat Commun. 2023 Sep 6;14(1):5451. doi: 10.1038/s41467-023-41061-8.
4
Deciphering the relational dynamics of AF-2 domain of PAN PPAR through drug repurposing and comparative simulations.通过药物再利用和比较模拟来破译 PAN PPAR 的 AF-2 结构域的关系动力学。
PLoS One. 2023 Mar 31;18(3):e0283743. doi: 10.1371/journal.pone.0283743. eCollection 2023.
5
Association of plasma metabolites and diagnostic imaging findings with hepatic lipidosis in bearded dragons (Pogona vitticeps) and effects of gemfibrozil therapy.血浆代谢物与诊断成像结果与鬃狮蜥（ Pogona vitticeps ）肝脂肪变性的关系及吉非贝齐治疗的效果。
PLoS One. 2023 Feb 3;18(2):e0274060. doi: 10.1371/journal.pone.0274060. eCollection 2023.
6
Cold-pressed raspberry seeds oil ameliorates high-fat diet triggered non-alcoholic fatty liver disease.冷榨树莓籽油可改善高脂饮食引发的非酒精性脂肪性肝病。
Saudi Pharm J. 2021 Nov;29(11):1303-1313. doi: 10.1016/j.jsps.2021.09.014. Epub 2021 Oct 6.
7
Beneficial Effects of Echinacoside on Diabetic Cardiomyopathy in Diabetic Mice.松果菊苷对糖尿病小鼠糖尿病心肌病的有益作用。
Drug Des Devel Ther. 2020 Dec 18;14:5575-5587. doi: 10.2147/DDDT.S276972. eCollection 2020.
8
Hepatic Transcriptome Analysis Revealing the Molecular Pathogenesis of Type 2 Diabetes Mellitus in Zucker Diabetic Fatty Rats.肝转录组分析揭示 2 型糖尿病发病机制在 Zucker 糖尿病肥胖大鼠中的作用。
Front Endocrinol (Lausanne). 2020 Nov 24;11:565858. doi: 10.3389/fendo.2020.565858. eCollection 2020.
9
Current treatment paradigms and emerging therapies for NAFLD/NASH.NAFLD/NASH 的现行治疗模式和新兴疗法。
Front Biosci (Landmark Ed). 2021 Jan 1;26(2):206-237. doi: 10.2741/4892.
10
History of Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病的历史。
Int J Mol Sci. 2020 Aug 16;21(16):5888. doi: 10.3390/ijms21165888.
本文引用的文献
1
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.罗格列酮心血管结局评估——一项中期分析。
N Engl J Med. 2007 Jul 5;357(1):28-38. doi: 10.1056/NEJMoa073394. Epub 2007 Jun 5.
2
Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes.苯扎贝特调节小鼠脂肪组织和3T3-L1脂肪细胞中11β-羟基类固醇脱氢酶1型的表达和酶活性。
Am J Physiol Endocrinol Metab. 2007 Apr;292(4):E1213-22. doi: 10.1152/ajpendo.00340.2006. Epub 2006 Dec 26.
3
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.一项关于吡格列酮治疗非酒精性脂肪性肝炎患者的安慰剂对照试验。
N Engl J Med. 2006 Nov 30;355(22):2297-307. doi: 10.1056/NEJMoa060326.
4
Stearoyl-CoA desaturase-1 mediates the pro-lipogenic effects of dietary saturated fat.硬脂酰辅酶A去饱和酶-1介导膳食饱和脂肪的促脂肪生成作用。
J Biol Chem. 2007 Jan 26;282(4):2483-93. doi: 10.1074/jbc.M610158200. Epub 2006 Nov 23.
5
Prevalence of fatty liver in children and adolescents.儿童和青少年脂肪肝的患病率。
Pediatrics. 2006 Oct;118(4):1388-93. doi: 10.1542/peds.2006-1212.
6
Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha.脂联素通过依次激活AMP活化蛋白激酶、p38丝裂原活化蛋白激酶和过氧化物酶体增殖物激活受体α来增加骨骼肌细胞中的脂肪酸氧化。
Diabetes. 2006 Sep;55(9):2562-70. doi: 10.2337/db05-1322.
7
Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver.非诺贝特是一种过氧化物酶体增殖物激活受体α激动剂，可减轻遗传性脂肪肝的Shionogi小鼠的肝脏脂肪变性和脂质过氧化。
Liver Int. 2006 Jun;26(5):613-20. doi: 10.1111/j.1478-3231.2006.01265.x.
8
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.多因素治疗对代谢综合征中非酒精性脂肪性肝病的影响：一项随机研究。
Curr Med Res Opin. 2006 May;22(5):873-83. doi: 10.1185/030079906X104696.
9
Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome.罗格列酮对代谢综合征患者内皮功能和炎症标志物的影响。
Diabetes Care. 2006 May;29(5):1071-6. doi: 10.2337/diacare.2951071.
10
Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study.长期补充n-3多不饱和脂肪酸可改善非酒精性脂肪性肝病患者的肝脂肪变性：一项初步研究。
Aliment Pharmacol Ther. 2006 Apr 15;23(8):1143-51. doi: 10.1111/j.1365-2036.2006.02885.x.
Zotero 插件